Study of Docosahexaenoic Acid (DHA) in Triple Negative Breast Cancer Survivors
Summary
The lay summary the sponsor registered on ClinicalTrials.gov.
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Ayca Gucalp
Memorial Sloan Kettering Cancer Center
Principal Investigator - Powel H. Brown, MD
M.D. Anderson Cancer Center
Study Chair
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
4 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Dana-Farber Cancer Institute
Boston, Massachusetts, United States
- Columbia University/herbert Irving Cancer Center
New York, New York, United States
- Memorial Sloan-Kettering Cancer Center
New York, New York, United States
- Md Anderson Cancer Center
Houston, Texas, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 31 May 2013
- Primary completion
- 11 Jan 2016
- Completion
- 22 Apr 2020
- Last update posted
- 28 Dec 2021
- Registered enrollment
- 65
- Registry id
- NCT01849250
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.